We conclude that the"AdipoR1-ESR1-CCNB1IP1-cyclin B1” axis has potential implications for developing predictive biomarkers and therapeutic targets in HCC patients (Fig. 7). Here, ESR1 is linked to hepatocellular carcinoma.